What is Erste Group Bank's Estimate for BSX FY2027 Earnings?

Key Points

• Erste Group Bank cut its FY2027 earnings estimate for Boston Scientific to $3.91 per share, down slightly from its prior $3.92 forecast.
• Despite the small revision, the stock retains a consensus Buy rating with a consensus target price of $106.27, although several firms have recently trimmed targets and litigation, guidance and volume concerns have pressured the shares.

Boston Scientific Corporation (NYSE:BSX - Free Report) - Equities researchers at Erste Group Bank cut their FY2027 earnings estimates for shares of Boston Scientific in a research note issued to investors on Tuesday, March 24th. Erste Group Bank analyst H. Engel now anticipates that the medical equipment provider will post earnings per share of $3.91 for the year, down from their prior estimate of $3.92. The consensus estimate for Boston Scientific's current full-year earnings is $2.85 per share.

Other analysts have also issued research reports about the company. Sanford C. Bernstein reiterated an "outperform" rating and set a $112.00 price objective on shares of Boston Scientific in a report on Friday, February 6th. Robert W. Baird reduced their target price on Boston Scientific from $118.00 to $101.00 and set an "outperform" rating on the stock in a research report on Thursday, February 5th. National Bank Financial set a $115.00 price target on Boston Scientific in a research note on Monday, February 2nd. Stifel Nicolaus lowered their price target on Boston Scientific from $110.00 to $90.00 and set a "buy" rating for the company in a report on Friday, March 20th. Finally, Weiss Ratings lowered Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, February 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $106.27.

Boston Scientific Price Performance

NYSE BSX opened at $69.70 on Thursday. The firm's fifty day simple moving average is $78.22 and its two-hundred day simple moving average is $91.25. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific has a 12-month low of $67.56 and a 12-month high of $109.50. The firm has a market capitalization of $103.59 billion, a P/E ratio of 35.93, a P/E/G ratio of 1.05 and a beta of 0.69.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the business posted $0.70 EPS. Boston Scientific's revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Norges Bank purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $2,199,395,000. Edgewood Management LLC acquired a new position in Boston Scientific in the 2nd quarter worth approximately $746,655,000. Parnassus Investments LLC raised its position in Boston Scientific by 42,978.9% during the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider's stock worth $672,128,000 after buying an additional 6,868,459 shares during the last quarter. Egerton Capital UK LLP lifted its stake in Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider's stock valued at $518,660,000 after acquiring an additional 3,671,548 shares during the period. Finally, Maverick Capital Ltd. acquired a new stake in Boston Scientific during the 4th quarter valued at approximately $280,735,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.50% of the stock is owned by company insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support: TD Cowen highlighted strong early adoption of BSX’s Agent DCB and kept a Buy rating with a $100 price target, underpinning bullish investor sentiment on multi-year growth potential. Boston Scientific’s Agent DCB: Strong Early Adoption and Underappreciated Multiyear Growth Opportunity
• Positive Sentiment: Potential rating upgrade / turnaround view: A Seeking Alpha piece argues BSX is “under pressure but could see a shift in fortunes,” suggesting a rating upgrade could help sentiment if upcoming operational data improves. Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
• Positive Sentiment: Bullish “buy the dip” narratives: MarketBeat and other bullish write-ups view the recent pullback as an opportunity tied to pending trial results and long-term device adoption, supporting short-term buying interest. Why Boston Scientific's Big Dip Could Be a Bigger Opportunity
• Neutral Sentiment: Industry note (unrelated company): Stratus Medical was named to Fortune’s Most Innovative Companies list — a positive for the RFA/chronic pain segment but not directly tied to BSX results. Investors may view it as a sector-level signal rather than company-specific news. Stratus Medical Recognized on Fortune's America's Most Innovative Companies List for 2026
• Negative Sentiment: Surge of securities-law firm notices and class-action filings allege misstatements around U.S. electrophysiology volumes; multiple firms (Bronstein, Faruqi, Levi & Korsinsky, Pomerantz, Rosen, Robbins, Bernstein Liebhard, etc.) are soliciting lead-plaintiff candidates and reminders about the May 4, 2026 deadline—heightening litigation risk and headline volatility for BSX. Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Recent stock weakness and volatility: News outlets and Zacks noted BSX shares have recently traded down more sharply than the broader market, reflecting investor concern over guidance, electrophysiology volumes, and litigation headlines. Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.